Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
312 stopped studies mapped to High Grade Astrocytic Tumor and descendants · 89% state a reason
Over the 312 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT06501911 | A Study of Bicalutamide With Brain Re-irradiation to Treat Recurrent/Progressive High… | Phase 1 | withdrawn | Jul 15, 2024 | University of Nebraska | PI leaving institution. | Other (stated, no rule matched) |
| NCT05563272 | 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors(STARBURST) | Phase 2 | terminated | Oct 3, 2022 | Telix Pharmaceuticals (Innovations) Pty Ltd | Indication scouting for TLX250-CDx will continue in theranostic studies, with a therapeutic… | Other (stated, no rule matched) |
| NCT04838782 | Role of Repeat Resection in Recurrent Glioblastoma | N/A | withdrawn | Apr 9, 2021 | University of Alberta | Insufficient patient population | Other (stated, no rule matched) |
| NCT03287063 | Study Using Genomic, Histologic and Radiomic Analysis to Evaluate Regional Tumor… | — | terminated | Sep 19, 2017 | University of Michigan Rogel Cancer Center | Enrollment and/or interactions/interventions were halted prematurely due to loss of funding. | Enrollment / accrual |
| NCT04406272 | VB-111 in Surgically Accessible Recurrent/Progressive GBM | Phase 2 | terminated | May 28, 2020 | Dana-Farber Cancer Institute | Trial stopped at request of VBL Therapeutics, as they are no longer pursuing their VB-111… | Other (stated, no rule matched) |
| NCT05297864 | PARP Inhibition for Gliomas (PI-4G or π4g)(OU-SCC-PI-4G) | Phase 2 | terminated | Mar 28, 2022 | University of Oklahoma | Funder terminated funding. | Funding |
| NCT05927610 | Genetic Testing of Cerebrospinal Fluid to Diagnose and Monitor Glioblastoma | N/A | withdrawn | Jul 3, 2023 | Memorial Sloan Kettering Cancer Center | Recruitment has not yet been initiated | Enrollment / accrual |
| NCT01430351 | Temozolomide, Memantine Hydrochloride, Mefloquine, and Metformin Hydrochloride in… | Phase 1 | terminated | Sep 8, 2011 | M.D. Anderson Cancer Center | \<75 % participant accrual | Enrollment / accrual |
| NCT04006119 | Study of Ad-RTS-hIL-12 + Veledimex in Combination With Cemiplimab in Subjects With… | Phase 2 | terminated | Jul 2, 2019 | Alaunos Therapeutics | Sponsor Decision | Sponsor / business decision |
| NCT05900908 | Post-operative Adjuvant Therapy w/wo GammaTile + Systemic Therapy(PATHWAyS) | Phase 4 | withdrawn | Jun 13, 2023 | GT Medical Technologies, Inc. | Study is being withdrawn in favor of a different study schema to be launched later this year. | Other (stated, no rule matched) |
| NCT04469699 | Stereotactical Photodynamic Therapy With 5-aminolevulinic Acid (Gliolan®) in Recurrent…(NOA11) | Phase 2 | terminated | Jul 14, 2020 | University Hospital Muenster | Poor recruitment | Enrollment / accrual |
| NCT05737212 | Studying the Safety, Efficacy, and Pharmacokinetic Characteristics of BNCT in Patients… | Phase 1 / Phase 2 | terminated | Feb 21, 2023 | Dawonmedax Co., Ltd. | The Phase 1 clinical trial was completed, and the study was stopped to initiate a Phase 2 trial… | Other (stated, no rule matched) |
| NCT02722512 | Trial of Heat Shock Protein Peptide Complex-96 (HSPPC-96) Vaccine | Phase 1 | terminated | Mar 30, 2016 | Ann & Robert H Lurie Children's Hospital of Chicago | Lack of substantial evidence for immune responses in response to vaccination. | Other (stated, no rule matched) |
| NCT05324501 | A Study of Intra-tumoral Administered MTX110 in Patients With Recurrent Glioblastoma(MAGIC-G1) | Phase 1 | terminated | Apr 12, 2022 | Biodexa Pharmaceuticals | Strategic decision | Sponsor / business decision |
| NCT01814813 | Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With… | Phase 2 | terminated | Mar 20, 2013 | Alliance for Clinical Trials in Oncology | DSMB futility analysis | Efficacy / futility |
| NCT03717142 | Feasibility of the LUM Imaging System for Detection of Cancer to the Brain | N/A | terminated | Oct 24, 2018 | Lumicell, Inc. | Initial data indicated a change in study design required prior to collecting additional data. | Other (stated, no rule matched) |
| NCT04397679 | Partial Brain RT, Temozolomide, Chloroquine, and TTF Therapy for the Treatment of Newly… | Phase 1 | terminated | May 21, 2020 | Barbara Ann Karmanos Cancer Institute | slow accrual | Enrollment / accrual |
| NCT06328036 | Testing the Combination of Anti-cancer Drugs Tiragolumab and Atezolizumab to Improve… | Phase 2 | withdrawn | Mar 25, 2024 | National Cancer Institute (NCI) | Other - Protocol moved to Disapproved | Other (stated, no rule matched) |
| NCT02525692 | Oral ONC201 in Adult Recurrent Glioblastoma | Phase 2 | terminated | Aug 17, 2015 | Jazz Pharmaceuticals | The Sponsor terminated the study to prioritize enrollment in a randomized Phase 3 trial of ONC201… | Safety / toxicity |
| NCT04421378 | A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or… | Phase 1 / Phase 2 | terminated | Jun 9, 2020 | Karyopharm Therapeutics Inc | Upon further consideration of the existing data and the competitive landscape, Karyopharm… | Other (stated, no rule matched) |
| NCT05973903 | Lenvatinib, Pembrolizumab, and Tumor Treating Fields (TTFields) for Second-line Treatment… | Phase 1 / Phase 2 | withdrawn | Aug 3, 2023 | Tel Aviv Medical Center | It was decided by the researcher not to open the study due to administrative issues. | Other (stated, no rule matched) |
| NCT04128774 | Function and Composition of Regulatory B Cells in Participants With Glioblastoma(GBMdexaB) | — | terminated | Oct 16, 2019 | Amsterdam UMC, location VUmc | To few participants | Other (stated, no rule matched) |
| NCT05879120 | Randomized Study of Neo-adjuvant and Adjuvant Pembrolizumab With and Without Targeted… | Phase 2 | withdrawn | May 30, 2023 | M.D. Anderson Cancer Center | PI Request | Other (stated, no rule matched) |
| NCT02372409 | Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain… | Phase 2 | terminated | Feb 26, 2015 | Washington University School of Medicine | Low accruals and competing clinical trials | Enrollment / accrual |
| NCT03973918 | Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG(BRAF) | Phase 2 | terminated | Jun 4, 2019 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCI decided to terminate ABTC Consortium due to NCI moving in different direction for Brain Cancer | Other (stated, no rule matched) |
| NCT04952571 | Combined Treatment of Camrelizumab and Bevacizumab for Adult Patients with Recurrent… | Phase 2 | terminated | Jul 7, 2021 | Beijing Sanbo Brain Hospital | Lack of funds | Funding |
| NCT03363659 | Disulfiram and Copper Gluconate With Temozolomide in Unmethylated Glioblastoma Multiforme | Phase 2 | terminated | Dec 6, 2017 | Wake Forest University Health Sciences | Investigator decision | Investigator |
| NCT05773664 | Dexamethasone and Azeliragon for Management of Post-Resection Cerebral Edema in Patients… | Phase 1 | withdrawn | Mar 17, 2023 | City of Hope Medical Center | Funding | Funding |
| NCT00555399 | Vorinostat, Isotretinoin and Temozolomide in Adults With Recurrent Glioblastoma… | Phase 1 / Phase 2 | terminated | Nov 8, 2007 | M.D. Anderson Cancer Center | No Sponsor funding for continuation of trial | Funding |
| NCT03539731 | [18F]DASA-23 and PET Scan in Evaluating Pyruvate Kinase M2 Expression in Patients With… | Phase 1 | terminated | May 29, 2018 | Guido A. Davidzon, MD, SM | study did not meet its objectives due to difficulties in enrollment | Enrollment / accrual |
| NCT04324840 | A Study of CC-90010 in Combination With Temozolomide With or Without Radiation Therapy in… | Phase 1 | terminated | Mar 27, 2020 | Celgene | Business objectives have changed | Sponsor / business decision |
| NCT05370508 | A Study of Sonodynamic Therapy Using SONALA-001 and Exablate 4000 Type 2.0 in Subjects… | Phase 1 / Phase 2 | terminated | May 11, 2022 | SonALAsense, Inc. | Study is terminated due to funding challenges and not due to safety concerns. | Safety / toxicity |
| NCT04047303 | CNS Penetration, PK and PD of Preoperative CC-90010 in Progressive/Recurrent Diffuse… | Phase 1 | terminated | Aug 6, 2019 | Celgene | Business objectives have changed. | Sponsor / business decision |
| NCT03250299 | Microtubule-Targeted Agent BAL101553 and Radiation Therapy in Treating Patients With… | Phase 1 | terminated | Aug 15, 2017 | Basilea Pharmaceutica | Due to the National Cancer Institute's (NCI)-mandated termination of the Adult Brain Tumor… | Other (stated, no rule matched) |
| NCT04221061 | 18F-FluorThanatrace (PET/CT) in Glioblastoma | Early Phase 1 | terminated | Jan 9, 2020 | University of Pennsylvania | Companion treatment trial closed early with negative results. No imaging study participants… | Other (stated, no rule matched) |
| NCT04915404 | Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme (WHO Grade IV) | Phase 1 / Phase 2 | terminated | Jun 7, 2021 | WPD Pharmaceuticals Sp. z o.o. | Business decision | Sponsor / business decision |
| NCT01622764 | 89Zr-RO5323441 PET Imaging in Glioblastoma | Phase 2 | withdrawn | Jun 19, 2012 | University Medical Center Groningen | No funding from the sponsor | Funding |
| NCT05074992 | A Trial of Neoadjuvant Therapy in Patients With Newly Diagnosed Glioblastoma(NeAT Glio) | Phase 2 | terminated | Oct 12, 2021 | University College, London | Support withdrawn from drug company supplying IMP | Sponsor / business decision |
| NCT04681677 | Recurrent GBM Treated With Neurosurgical Resection and IORT Using the Xoft Axxent eBx…(IORT) | Phase 2 | terminated | Dec 23, 2020 | Xoft, Inc. | unspecified business decision | Sponsor / business decision |
| NCT02085304 | Tumor Resection and Gliadel® Wafers, Followed by Temodar® With Standard Radiation or… | Phase 1 / Phase 2 | terminated | Mar 12, 2014 | St. Joseph's Hospital and Medical Center, Phoenix | met stopping rules for futility | Efficacy / futility |
| NCT02880410 | Feasibility Study on LITT for Newly Diagnosed Glioblastoma(FLAG) | Phase 1 | terminated | Aug 26, 2016 | Monteris Medical | Terminated (failure to enroll) | Enrollment / accrual |
| NCT03927222 | Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed WHO Grade…(I-ATTAC) | Phase 2 | terminated | Apr 25, 2019 | Mustafa Khasraw, MBChB, MD, FRCP, FRACP | Resource shortage | Other (stated, no rule matched) |
| NCT05304663 | Safety and Efficacy of Different Administration Sequences of L19TNF With Lomustine in…(GLIOASTRA) | Phase 1 | withdrawn | Mar 31, 2022 | Philogen S.p.A. | The Sponsor had no further plan for the study in object | Other (stated, no rule matched) |
| NCT02133183 | Sapanisertib Before and After Surgery in Treating Patients With Recurrent Glioblastoma | Phase 1 | terminated | May 7, 2014 | National Cancer Institute (NCI) | Other - Lapse in funding | Funding |
| NCT02546102 | Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma | Phase 3 | suspended | Sep 10, 2015 | Precision Life Sciences Group | Company is discussing with FDA to reinitiate the trial now. | Sponsor / business decision |
| NCT05666349 | Reirradiation and Niraparib in Patients With Recurrent Glioblastoma(RiNG) | Phase 1 | withdrawn | Dec 27, 2022 | University College, London | Funder support withdrawn 13-Oct-2023. Study did not open to recruitment. | Enrollment / accrual |
| NCT03705351 | Tumor Treating Fields With Chemoradiation in Newly Diagnosed GBM | Phase 1 | terminated | Oct 15, 2018 | Providence Health & Services | Prinicipal Investigator departure from institution | Investigator |
| NCT02905643 | Discerning Pseudoprogression vs True Tumor Growth in GBMs | — | terminated | Sep 19, 2016 | Ascension Health | Investigator left institution | Investigator |
| NCT02168270 | Temozolomide and Ascorbic Acid in Treating Patients With Recurrent High-Grade Glioma | Phase 1 | terminated | Jun 20, 2014 | University of Nebraska | not stated | Not stated |
| NCT04629209 | A Phase II, Open Label Study of ONC201 in Adults With EGFR-low Glioblastoma | Phase 2 | withdrawn | Nov 16, 2020 | Masonic Cancer Center, University of Minnesota | Change in approach to study. | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Jul 22, 2025source: clinicaltrials